| Field | Specification |
|---|---|
| Target | |
| Alternative names | CD 16; CD 16a; CD16; CD16a; CD16a antigen; CD16B; CD16b antigen; Fc fragment of IgG; Fc fragment of IgG low affinity IIIa receptor (CD16); Fc fragment of IgG low affinity IIIa receptor; Fc fragment of IgG receptor IIIa; Fc fragment of IgG; low affinity III; receptor (CD16); Fc fragment of IgG; low affinity III; receptor for (CD16); Fc fragment of IgG; low affinity IIIa; receptor (CD16); Fc fragment of IgG; low affinity IIIa; receptor (CD16a); Fc fragment of IgG; low affinity IIIa; receptor for; Fc fragment of IgG; low affinity IIIb; receptor (CD16b); Fc fragment of IgG; low affinity IIIb; receptor for (CD16); Fc gamma R3; Fc gamma receptor III 2 (CD 16); Fc gamma receptor III A; Fc gamma receptor IIIA; Fc gamma receptor IIIb (CD 16); Fc gamma RIII alpha; Fc gamma RIII; Fc gamma RIII beta; Fc gamma RIIIa; Fc gamma RIIIb; Fc of IgG; Fc-gamma receptor III2 (CD 16); Fc-gamma receptor III2 (CD16); Fc-gamma receptor IIIb (CD16); Fc-gamma RIII; Fc-gamma RIII-alpha; Fc-gamma RIIIa; FCG 3; FCG3; FCG3A_HUMAN; FCgammaRIIIA; FCGR 3; FCGR 3A; FCGR3; FCGR3A; FCGR3A protein; FCGRIII; FCGRIII-2; FcR 10; FcR-10; FcR10; FcRIII; FcRIIIa; IGFR 3; IGFR3; IgG Fc receptor III 1; IgG Fc receptor III 2; IgG Fc receptor III-2; IMD20; immunoglobulin G Fc receptor III; immunoglobulin G Fc receptor III-2; Low affinity IIIa receptor; Low affinity immunoglobulin gamma Fc region receptor III A; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor IIIB; neutrophil-specific antigen NA |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Fusion protein of Human FCGR3A |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This is a polyclonal anti-FCGR3A antibody raised in Rabbit, with confirmed utility in ELISA, IHC. It is designed to detect FCGR3A protein in Human and supports researchers working in immunology contexts where consistent antibody performance is required.
Key elements and design rationale
- Immunogen: Fusion protein of Human FCGR3A — the immunizing antigen determines the epitope region; confirm epitope compatibility with sample preparation and expected post-translational modifications.
- Host species (Rabbit): Requires anti-rabbit-IgG secondary reagents. Use matched secondaries to avoid no-signal or cross-reactivity issues.
- Polyclonal format: Recognizes multiple epitopes, providing robust signal across varied preparations and species variants. Inherent lot-to-lot variability requires appropriate controls.
- Isotype (IgG): Compatible with standard Protein A/G purification and widely supported by secondary reagents. Include an isotype-matched control at equivalent concentration.
- Purification (Antigen affinity purification): Enriches for specific immunoglobulin classes, reducing non-specific populations and improving signal-to-noise.
Biological background
FCGR3A (also referred to as CD 16, CD 16a, CD16, CD16a, CD16a antigen, CD16B, CD16b antigen, Fc fragment of IgG, Fc fragment of IgG low affinity IIIa receptor (CD16), Fc fragment of IgG low affinity IIIa receptor, Fc fragment of IgG receptor IIIa, Fc fragment of IgG, low affinity III, receptor (CD16), Fc fragment of IgG, low affinity III, receptor for (CD16), Fc fragment of IgG, low affinity IIIa, receptor (CD16), Fc fragment of IgG, low affinity IIIa, receptor (CD16a), Fc fragment of IgG, low affinity IIIa, receptor for, Fc fragment of IgG, low affinity IIIb, receptor (CD16b), Fc fragment of IgG, low affinity IIIb, receptor for (CD16), Fc gamma R3, Fc gamma receptor III 2 (CD 16), Fc gamma receptor III A, Fc gamma receptor IIIA, Fc gamma receptor IIIb (CD 16), Fc gamma RIII alpha, Fc gamma RIII, Fc gamma RIII beta, Fc gamma RIIIa, Fc gamma RIIIb, Fc of IgG, Fc-gamma receptor III2 (CD 16), Fc-gamma receptor III2 (CD16), Fc-gamma receptor IIIb (CD16), Fc-gamma RIII, Fc-gamma RIII-alpha, Fc-gamma RIIIa, FCG 3, FCG3, FCG3A_HUMAN, FCgammaRIIIA, FCGR 3, FCGR 3A, FCGR3, FCGR3A, FCGR3A protein, FCGRIII, FCGRIII-2, FcR 10, FcR-10, FcR10, FcRIII, FcRIIIa, IGFR 3, IGFR3, IgG Fc receptor III 1, IgG Fc receptor III 2, IgG Fc receptor III-2, IMD20, immunoglobulin G Fc receptor III, immunoglobulin G Fc receptor III-2, Low affinity IIIa receptor, Low affinity immunoglobulin gamma Fc region receptor III A, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor IIIB, neutrophil-specific antigen NA) is a protein target studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection and experimental design. Consult UniProt, NCBI Gene, and primary literature for current annotation of FCGR3A biology, including known isoforms, interactors, and disease-relevant expression patterns in immunology.
Common research applications
- ELISA: Sandwich or indirect ELISA can quantify soluble target in biological fluids or culture supernatants. Ensure samples fall within the linear detection range.
- IHC: IHC visualizes target in FFPE or frozen tissue sections. Optimize antigen retrieval method and secondary detection for each tissue type.
Notes for experimental interpretation
- Isotype controls: Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.
- Cross-reactivity: Polyclonal preparations may cross-react with related proteins or isoforms. Orthogonal validation (siRNA, KO lysate, recombinant protein) is recommended to confirm signal specificity.
- Matrix effects: Sample matrix (serum, plasma, lysate, homogenate) can affect performance. Pilot dilution linearity and spike-recovery experiments are recommended for quantitative studies.
- Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation given potential epitope sequence divergence.
This product is a polyclonal antibody purified from rabbit antiserum.
FCGR3A is a protein target in Human biology. This polyclonal antibody raised in Rabbit is designed to detect FCGR3A in ELISA, IHC applications, with IgG isotype.
This antibody is reported reactive against Human. The immunogen was derived from Human. Cross-reactivity with other species should not be assumed without documented data or empirical testing.
The supplier reports performance in ELISA, IHC. Each application requires independent dilution optimization, blocking conditions, and appropriate controls. Performance in unlisted applications requires empirical testing.
This is a non-conjugated IgG antibody requiring a compatible secondary for detection. Select an anti-rabbit IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin), matched to IgG.
Recommended: (1) Isotype control — IgG from Rabbit at matching concentration for non-specific background; (2) Positive control — known FCGR3A-expressing cell/tissue; (3) Negative control — knockdown or knockout sample to confirm signal specificity; (4) Dilution linearity — verify proportional signal decrease to confirm quantitative linearity in your matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
